Featured Research

from universities, journals, and other organizations

'Benign' MS May Not Be So Benign

Date:
February 13, 2007
Source:
American Academy of Neurology
Summary:
People who have multiple sclerosis (MS) for 10 years and have few of the disabling symptoms of the disease are often told they have "benign MS" and that their symptoms will likely not ever occur to the same extent as other people with MS. A new study, published in the Feb. 13, 2007, issue of Neurology, the scientific journal of the American Academy of Neurology, shows that unfortunately this may not be correct.

People who have multiple sclerosis (MS) for 10 years and have few of the disabling symptoms of the disease are often told they have "benign MS" and that their symptoms will likely not ever occur to the same extent as other people with MS. A new study, published in the February 13, 2007, issue of Neurology®, the scientific journal of the American Academy of Neurology, shows that unfortunately this may not be correct.

After 20 years, the disease had progressed in nearly half of those whose MS was benign at 10 years, according to the study.

The study of 169 people whose MS was benign after 10 years found that after 20 years the disease had progressed in 21 percent to the extent that they needed a cane to walk. Most of the patients had the relapsing-remitting form of the disease, where symptoms come and go. But after 20 years, about 20 percent of the people had developed the secondary-progressive form of the disease, where the disease steadily progresses.

"We need to be careful what we tell people, and not give them false hope that their symptoms may never get worse," said lead study author Ana-Luiza Sayao, MD, of the University of British Columbia in Vancouver, Canada.

"We hoped to identify risk factors that make people more likely to progress in the disease after 10 years of a benign course, but we did not find that gender, the symptoms when the disease began, or age when the disease began were associated with either disease progression or remaining benign," said study author Virginia Devonshire, MD, of the University of British Columbia in Vancouver, Canada. "More research needs to be done to identify criteria to determine which people will remain with mild disability over the long term."

The study was supported in part by a Don Paty Career Development Award from the MS Society of Canada and the Christopher Foundation.


Story Source:

The above story is based on materials provided by American Academy of Neurology. Note: Materials may be edited for content and length.


Cite This Page:

American Academy of Neurology. "'Benign' MS May Not Be So Benign." ScienceDaily. ScienceDaily, 13 February 2007. <www.sciencedaily.com/releases/2007/02/070212185344.htm>.
American Academy of Neurology. (2007, February 13). 'Benign' MS May Not Be So Benign. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2007/02/070212185344.htm
American Academy of Neurology. "'Benign' MS May Not Be So Benign." ScienceDaily. www.sciencedaily.com/releases/2007/02/070212185344.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins